Protocol

Part of the series Methods in Pharmacology and Toxicology pp 1-21

Date:

Targeting Glioma Cancer Cells with Fluorescent Nanodiamonds via Integrin Receptors

  • Jitka NeburkovaAffiliated withInstitute of Organic Chemistry and Biochemistry of the CASFirst Faculty of Medicine, Charles University
  • , Miroslav HajekAffiliated withInstitute of Organic Chemistry and Biochemistry of the CAS
  • , Ivan RehorAffiliated withInstitute of Organic Chemistry and Biochemistry of the CAS
  • , Jiri SchimerAffiliated withInstitute of Organic Chemistry and Biochemistry of the CAS
  • , Frantisek SedlakAffiliated withInstitute of Organic Chemistry and Biochemistry of the CASFirst Faculty of Medicine, Charles UniversityDepartment of Genetics and Microbiology, Faculty of Science, Charles University
  • , Jan StursaAffiliated withNuclear Physics Institute of the CAS
  • , Martin HrubyAffiliated withInstitute of Macromolecular Chemistry of the CAS
  • , Petr CiglerAffiliated withInstitute of Organic Chemistry and Biochemistry of the CAS Email author 

* Final gross prices may vary according to local VAT.

Get Access

Abstract

Glioblastomas, aggressive and highly vascularized brain tumors, overexpress αvβ3 integrins, which are widely exploited for cancer diagnostics and therapy. Proteins and peptides containing the RGD sequence bind αvβ3 integrins. Here, we describe detailed protocols for preparation and testing of fluorescent nanodiamonds coated with a biocompatible N-(2-hydroxypropyl)methacrylamide copolymer shell. When the surface of these particles was modified with a cyclic RGD peptide, they selectively targeted integrin αvβ3 receptors on U-87 MG glioblastoma cells with high internalization efficacy. The modified particles enabled background-free near-infrared imaging of cells, showed excellent colloidal stability in culture media, and exhibited negligible cytotoxicity.

Keywords

Background-free imaging Fluorescent nanodiamond Glioma RGD peptide Targeting αvβ3 integrin